GLP-1 agonists are FDA-approved drugs used in the treatment of type 2 diabetes mellitus and obesity as they increase insulin release, decrease glucagon production, enhance proliferation of pancreatic beta cells, and delay gastric emptying (Collins and Costello 2024). The gene discussed is GLP1R; the disease is obesity disorder.